MXPA04007396A - Proceso para la elaboracion de inhibidores de reductasa hmg-coa. - Google Patents
Proceso para la elaboracion de inhibidores de reductasa hmg-coa.Info
- Publication number
- MXPA04007396A MXPA04007396A MXPA04007396A MXPA04007396A MXPA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A MX PA04007396 A MXPA04007396 A MX PA04007396A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- hmg
- coa reductase
- reductase inhibitors
- salt
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35378702P | 2002-01-31 | 2002-01-31 | |
| PCT/EP2003/000954 WO2003064392A1 (en) | 2002-01-31 | 2003-01-30 | Process for the manufacture of hmg-coa reductase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007396A true MXPA04007396A (es) | 2004-10-11 |
Family
ID=27663254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007396A MXPA04007396A (es) | 2002-01-31 | 2003-01-30 | Proceso para la elaboracion de inhibidores de reductasa hmg-coa. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7371865B2 (https=) |
| EP (1) | EP1472228B1 (https=) |
| JP (1) | JP4524111B2 (https=) |
| KR (1) | KR20040081161A (https=) |
| CN (1) | CN1305853C (https=) |
| AT (1) | ATE426594T1 (https=) |
| AU (1) | AU2003226971B2 (https=) |
| BR (1) | BR0307303A (https=) |
| CA (1) | CA2472776C (https=) |
| CO (1) | CO5601005A2 (https=) |
| DE (1) | DE60326819D1 (https=) |
| EC (1) | ECSP045214A (https=) |
| ES (1) | ES2323267T3 (https=) |
| IL (1) | IL162980A (https=) |
| MX (1) | MXPA04007396A (https=) |
| NO (1) | NO327091B1 (https=) |
| NZ (1) | NZ534232A (https=) |
| PL (1) | PL370658A1 (https=) |
| PT (1) | PT1472228E (https=) |
| RU (1) | RU2299196C2 (https=) |
| WO (1) | WO2003064392A1 (https=) |
| ZA (1) | ZA200405322B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202004021379U1 (de) * | 2003-02-12 | 2008-02-21 | Ciba Specialty Chemicals Holding Inc. | Kristalline Formen von Pitivastatin Calcium |
| CN100408562C (zh) * | 2003-04-24 | 2008-08-06 | 大赛璐化学工业株式会社 | (3r,5s,6e)-7-[2-环丙基-4-(4-氟苯基)喹啉-3-基]-3,5-二羟基-6-庚烯酸乙酯的制备方法 |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| WO2006035286A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| US8455640B2 (en) * | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
| US8404841B2 (en) * | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| US7687660B2 (en) * | 2007-04-18 | 2010-03-30 | Teva Pharmaceutical Industries Ltd. | Process for preparing intermediates of HMG-CoA reductase inhibitors |
| US20090069563A1 (en) * | 2007-07-12 | 2009-03-12 | Valerie Niddam-Hildesheim | Rosuvastatin intermediates and their preparation |
| US8487105B2 (en) * | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| KR101160152B1 (ko) * | 2009-02-24 | 2012-06-27 | 한미사이언스 주식회사 | 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물 |
| WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| WO2011104725A2 (en) * | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
| EP2383260A3 (en) | 2010-04-30 | 2011-12-28 | Dipharma Francis S.r.l. | Process for the preparation of statins |
| WO2011141934A1 (en) | 2010-05-13 | 2011-11-17 | Matrix Laboratories Ltd. | An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors |
| JP5822169B2 (ja) * | 2010-07-01 | 2015-11-24 | ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ | ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法 |
| EP3178812A1 (en) * | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| EP2785851A2 (en) | 2011-11-28 | 2014-10-08 | Mylan Laboratories, Limited | Process for producing chiral statin side chain intermediates employing candida antarctica lipase b |
| CN103288871A (zh) * | 2012-02-28 | 2013-09-11 | 浙江京新药业股份有限公司 | 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用 |
| ITVI20130039A1 (it) | 2013-02-20 | 2014-08-21 | F I S Fabbrica Italiana Sint I S P A | Processo per la preparazione di intermedi chiave per la sintesi di statine |
| CN103172656B (zh) * | 2013-04-02 | 2015-07-08 | 浙江科技学院 | 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺 |
| CN111518035A (zh) * | 2020-06-18 | 2020-08-11 | 安徽鼎旺医药有限公司 | 一种瑞舒伐他汀叔丁胺盐及其制备方法 |
| CN113683539B (zh) * | 2021-09-23 | 2023-05-16 | 上海裕兰生物科技有限公司 | 一种聚酮中间体的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4650890A (en) * | 1984-04-03 | 1987-03-17 | Sandoz Corp. | Preparation of olefinic compounds and intermediates thereof |
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
| DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
| US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
| DK0484614T3 (da) * | 1990-05-11 | 1995-06-12 | American Cyanamid Co | N-Acylerede arylpyrroler, der kan anvendes som insekticide, akaricide, nematodicide og molluscicide midler |
| JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| CA2427255A1 (en) * | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| KR100883874B1 (ko) * | 2001-02-02 | 2009-02-17 | 미쯔비시 가가꾸 가부시끼가이샤 | (3ｒ,5ｓ)-(ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법 |
| EP1466905B1 (en) * | 2001-11-14 | 2011-05-18 | Nissan Chemical Industries, Ltd. | Process for producing optically active oxoheptenoic acid ester |
| US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
| GB0210234D0 (en) * | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
-
2003
- 2003-01-30 AU AU2003226971A patent/AU2003226971B2/en not_active Ceased
- 2003-01-30 PT PT03734716T patent/PT1472228E/pt unknown
- 2003-01-30 WO PCT/EP2003/000954 patent/WO2003064392A1/en not_active Ceased
- 2003-01-30 CA CA2472776A patent/CA2472776C/en not_active Expired - Fee Related
- 2003-01-30 RU RU2004126442/04A patent/RU2299196C2/ru not_active IP Right Cessation
- 2003-01-30 ES ES03734716T patent/ES2323267T3/es not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011808A patent/KR20040081161A/ko not_active Abandoned
- 2003-01-30 JP JP2003564015A patent/JP4524111B2/ja not_active Expired - Lifetime
- 2003-01-30 US US10/502,177 patent/US7371865B2/en not_active Expired - Lifetime
- 2003-01-30 DE DE60326819T patent/DE60326819D1/de not_active Expired - Lifetime
- 2003-01-30 PL PL03370658A patent/PL370658A1/xx not_active Application Discontinuation
- 2003-01-30 AT AT03734716T patent/ATE426594T1/de active
- 2003-01-30 MX MXPA04007396A patent/MXPA04007396A/es active IP Right Grant
- 2003-01-30 CN CNB038027402A patent/CN1305853C/zh not_active Expired - Lifetime
- 2003-01-30 EP EP03734716A patent/EP1472228B1/en not_active Expired - Lifetime
- 2003-01-30 BR BR0307303-3A patent/BR0307303A/pt not_active IP Right Cessation
- 2003-01-30 NZ NZ534232A patent/NZ534232A/xx not_active IP Right Cessation
-
2004
- 2004-07-05 ZA ZA2004/05322A patent/ZA200405322B/en unknown
- 2004-07-12 IL IL162980A patent/IL162980A/en not_active IP Right Cessation
- 2004-07-30 EC EC2004005214A patent/ECSP045214A/es unknown
- 2004-08-10 CO CO04077715A patent/CO5601005A2/es not_active Application Discontinuation
- 2004-08-30 NO NO20043611A patent/NO327091B1/no not_active IP Right Cessation
-
2008
- 2008-03-24 US US12/054,193 patent/US20080182873A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080182873A1 (en) | 2008-07-31 |
| CN1622937A (zh) | 2005-06-01 |
| KR20040081161A (ko) | 2004-09-20 |
| RU2299196C2 (ru) | 2007-05-20 |
| CA2472776C (en) | 2011-01-25 |
| EP1472228A1 (en) | 2004-11-03 |
| JP2005520814A (ja) | 2005-07-14 |
| NO20043611L (no) | 2004-08-30 |
| US20050070605A1 (en) | 2005-03-31 |
| ATE426594T1 (de) | 2009-04-15 |
| PL370658A1 (en) | 2005-05-30 |
| PT1472228E (pt) | 2009-06-24 |
| CN1305853C (zh) | 2007-03-21 |
| ES2323267T3 (es) | 2009-07-10 |
| IL162980A (en) | 2010-02-17 |
| EP1472228B1 (en) | 2009-03-25 |
| US7371865B2 (en) | 2008-05-13 |
| JP4524111B2 (ja) | 2010-08-11 |
| BR0307303A (pt) | 2005-01-11 |
| NO327091B1 (no) | 2009-04-20 |
| RU2004126442A (ru) | 2005-06-10 |
| HK1070651A1 (en) | 2005-06-24 |
| ECSP045214A (es) | 2004-09-28 |
| WO2003064392A1 (en) | 2003-08-07 |
| CO5601005A2 (es) | 2006-01-31 |
| DE60326819D1 (de) | 2009-05-07 |
| AU2003226971B2 (en) | 2006-11-30 |
| NZ534232A (en) | 2006-03-31 |
| ZA200405322B (en) | 2005-07-27 |
| CA2472776A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04007396A (es) | Proceso para la elaboracion de inhibidores de reductasa hmg-coa. | |
| DE60239428D1 (https=) | ||
| MXPA04008613A (es) | N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv. | |
| WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
| GB0100889D0 (en) | Compounds | |
| MXPA05009969A (es) | Metodo para aislar la forma cristalina i de la 5-azacitidina. | |
| GB0401088D0 (en) | Phosphoramidate derivatives | |
| CA2665931C (en) | Hydrobenzamide derivatives as inhibitors of hsp90 | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| WO2012002741A3 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
| PL1742642T3 (pl) | Analogi fosfonianowe związków inhibitorów integrazy HIV | |
| MXPA05009611A (es) | Piperidinas sustituidas como nuevos inhibidores de mdm2-p53. | |
| TNSN05105A1 (en) | Novel bicyclic inhibitors of hormone sensitive lipase | |
| PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
| BR0307801A (pt) | Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase | |
| SG144736A1 (en) | Synthesis of temozolomide and analogs | |
| MX2007004698A (es) | Sintesis asimetrica de dihidrobenzofuranos sustituidos. | |
| MXPA05013584A (es) | Compuesto amina terciaria ciclica. | |
| EA200300804A1 (ru) | Усовершенствованный способ получения карбапенема | |
| TW200640912A (en) | Novel processes for the preparation of a 2H-chromene | |
| WO2005085236A3 (en) | Caspase inhibitors and uses thereof | |
| SG143062A1 (en) | Synthesis of temozolomide and analogs | |
| NZ512207A (en) | Process for producing quinolinecarbaldehyde | |
| MY129094A (en) | Condensed polycyclic compounds | |
| TW200621785A (en) | Analgesic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |